Clinical Trials on Steroid Refractory Chronic Graft Versus Host Disease (SR cGVHD)

Total 1074 results

Anhui Provincial Hospital

Recruiting

A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD

Steroid-refractory Acute Graft-versus-host Disease(SR-aGVHD)

China
The Korean Society of Hematopoietic Stem Cell Transplantation
Hoffmann-La Roche

Unknown

Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease

Steroid-Refractory Chronic GVHD

Korea, Republic of
Novartis Pharmaceuticals

Available

Managed Access Programs for INC424, Ruxolitinib

Primary Myelofibrosis (PMF) | Polycythemia Vera (PV) | Post Polycythemia Myelofibrosis (PPV MF) | Thrombocythemia Myelofibrosis (PET-MF) | Severe/Very Severe COVID-19 Illness | Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD) | Steroid Refractory Chronic Graft Versus Host Disease...
Columbia University
Incyte Corporation

Terminated

Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease (GVHD)

Graft Vs Host Disease | Steroid Refractory GVHD

United States
MaaT Pharma

Recruiting

MaaT013 as Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients (ARES)

Acute Graft Versus Host Disease in Intestine | Steroid Refractory GVHD

Spain, France, Germany, Austria, Belgium, Italy
MaaT Pharma

Available

Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease (ATLAS)

Acute Graft Versus Host Disease in Intestine | Steroid Refractory GVHD

France
Nationwide Children's Hospital

Terminated

Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease

Graft Versus Host Disease | Acute GVH Disease | Steroid Refractory GVHD

United States
Jules Bordet Institute
Macopharma; Belgian Hematological Society

Recruiting

Extracorporeal Photopheresis Using Theraflex ECP™ for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD)

Refractory Chronic Graft Versus Host Disease (cGVHD)

Belgium
ReAlta Life Sciences, Inc.

Not yet recruiting

Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease (AURORA)

Steroid Refractory GVHD
University of Liege

Terminated

Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD)

Chronic Graft-Versus-Host Disease | Acute Graft-Versus-Host Disease | Steroid Refractory Graft-Versus-Host Disease

Belgium
MaaT Pharma

Recruiting

Prospective Interventional Study Exploring the Microbiota Recolonization in SR-GvHD Patients Receiving MaaT013 (ORION)

Steroid Refractory GVHD | Intestinal GVHD

France
Equillium
Biocon Limited

Recruiting

A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)

Graft Versus Host Disease | GVHD | aGVHD | Acute-graft-versus-host Disease | Acute GVHD

United States, Korea, Republic of, Germany, Israel, Spain, Belgium, Italy, Australia, France, Canada, Portugal, New Zealand
Equillium
Biocon Limited

Recruiting

A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD (EQUATE)

GVHD | GVHD, Acute | aGVHD | Acute-graft-versus-host Disease

United States
AltruBio Inc.

Completed

Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host Disease

Steroid-refractory Acute Graft-versus-Host Disease | Treatment-refractory Acute Graft-versus-Host Disease

United States
Hannah Choe, MD
National Cancer Institute (NCI); Plexxikon

Terminated

Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD

Acute Graft Versus Host Disease | Steroid Refractory Graft Versus Host Disease

United States
Novartis Pharmaceuticals

Not yet recruiting

Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease

Steroid-refractory Acute Graft Versus Host Disease
medac GmbH

Recruiting

Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease (BALDER)

Steroid-refractory Acute Graft-versus-host Disease

Germany, Spain, France, Poland, Italy
Xenikos
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Terminated

T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802) (1802)

Steroid-Refractory Acute Graft Versus Host Disease

United States
Xenikos
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Terminated

A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002) (2002)

Steroid-Refractory Acute Graft Versus Host Disease

United States, Belgium, Croatia, France, Germany, Italy, Netherlands, Spain, United Kingdom
medac GmbH

Recruiting

Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy (IDUNN)

Steroid-refractory Acute Graft-versus-host Disease

Spain, Germany, France, Poland, Sweden
Nanfang Hospital of Southern Medical University

Unknown

Efficacy and Safety of FMT Capsule Treating Steroid-refractory GI-aGvHD

Steroid-refractory Gastrointestinal Acute Graft Versus Host Disease

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease

Hematopoietic and Lymphoid Cell Neoplasm | Steroid Refractory Graft Versus Host Disease

United States
Dana-Farber Cancer Institute

Completed

Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease

Graft vs Host Disease | Chronic Graft vs Host Disease | cGVHD

United States
Yi-Lun Wang

Completed

Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease

Steroid Refractory GVHD

Taiwan
Therakos, Inc., a Mallinckrodt Company

Terminated

Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease

Steroid Refractory Acute Graft Versus Host Disease

United States, Spain, France, Austria, Germany, Hungary, Italy, United Kingdom
Massachusetts General Hospital

Not yet recruiting

Tele-Palliative Care Intervention for Patients With Chronic Graft-Versus-Host Disease (cGVHDTele-PC)

Chronic GVHD | Chronic Graft-versus-host Disease | cGVHD

United States
Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Completed

Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)

Chronic GVHD

United States
M.D. Anderson Cancer Center

Completed

Feasibility Study of Collecting Multicenter Chronic GVHD Data

Graft-Versus-Host Disease

United States
University of Salamanca

Recruiting

Physiotherapy and Therapeutic Exercise Program in Graft-versus-host Disease (GvHD)

GVHD, Chronic | GVHD,Acute

Spain
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Completed

CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease

GVHD | Graft-versus-host-disease | GVHD, Acute

United States
Massachusetts General Hospital
Novartis

Terminated

Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT

Graft Versus Host Disease

United States
Samsung Medical Center
Medipost Co Ltd.

Unknown

Umbilical Cord Blood-derived Mesenchymal Stem Cells for the Treatment of Steroid-refractory Acute or Chronic Graft-versus-host-disease (GVHD-MSC)

Graft-Versus-Host Disease | GVHD | Disorder Related to Transplantation | Allogeneic Hematopoietic Transplant

Korea, Republic of
Washington University School of Medicine

Recruiting

Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease

Chronic GVHD | Acute Graft-versus-host Disease | Chronic Graft-versus-host Disease | Acute GVHD

United States
ElsaLys Biotech

Available

Early Access Program With Inolimomab in Steroid-refractory Acute Graft Versus Host Disease

Steroid Resistant Acute Graft Versus Host Disease

France
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease

Chronic Graft Versus Host Disease | Steroid Refractory Graft Versus Host Disease

United States
Hadassah Medical Organization

Completed

Alefacept for Chronic Graft Versus Host Disease

Resistant Chronic GVHD

Israel
Incyte Corporation

Completed

A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)

Graft-versus-host Disease (GVHD)

United States
Incyte Corporation

Completed

GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease

Graft-versus-host Disease (GVHD)

United States, Spain, Belgium, France, Italy, Korea, Republic of, Finland, United Kingdom, Germany, Israel, Switzerland, Austria, Australia, Czechia, Greece, New Zealand, Poland, Portugal, Taiwan
Incyte Corporation

Completed

Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD

Graft-versus-host Disease (GVHD)

United States
CSL Behring
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Active, not recruiting

Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705)

Graft Versus Host Disease (GVHD)

United States
Incyte Corporation

Approved for marketing

Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD

Graft-versus-host Disease (GVHD)
Institute of Hematology & Blood Diseases Hospital

Recruiting

Umbilical Cord Mesenchymal Stem Cells as First-line Treatment for Patients With Acute Graft Versus Host Disease

aGVHD

China
Incyte Corporation

Completed

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Graft-versus-host Disease (GVHD)

Belgium, Italy, Spain, Saudi Arabia, Turkey, United Kingdom, Germany, Greece, Canada, Austria, France, Israel, Netherlands, Sweden, Switzerland, Korea, Republic of, Bulgaria, Japan, Norway, Czechia, Russian Federation, Jordan, Hungary, Ind... and more
Incyte Corporation

Approved for marketing

An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

Graft-versus-host Disease (GVHD)

United States
John Levine

Completed

Itacitinib for Low Risk GVHD

GVHD | Low Risk Acute Graft-versus-host Disease | Graft-versus-host-disease

United States
Jonsson Comprehensive Cancer Center

Withdrawn

Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease

Acute Graft Versus Host Disease | Gastrointestinal Tract Acute Graft Versus Host Disease | Severe Gastrointestinal Tract Acute Graft Versus Host Disease | Steroid Resistant Gastrointestinal Tract Acute Graft Versus Host Disease

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Biomarkers in Predicting Response in Patients With Graft-Versus-Host Disease Undergoing Extracorporeal Photophoresis

Graft Versus Host Disease (GVHD)

United States
Regimmune Corporation

Completed

RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation

Graft Vs Host Disease | Graft-versus-host-disease | Acute-graft-versus-host Disease | Prevention of aGVHD

United States
Leland Metheny

Withdrawn

Fecal Microbiota Transplantation For The Treatment Of Gastro-Intestinal Acute GVHD

Gastro-Intestinal Acute Graft Versus Host Disease (GI-aGVHD)

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

Chronic Graft Versus Host Disease | Hematologic and Lymphocytic Disorder | Steroid Refractory Graft Versus Host Disease

United States

Clinical Trials on Steroid Refractory Chronic Graft Versus Host Disease (SR cGVHD)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations